Market Research Reports Global Leukemia Treatment Drugs Market Report 2019 | Page 2

Increasing patient awareness regarding latest technological advancements in therapies, and benefits
such as tolerability, efficacy & safety are the factors expected to contribute growth of this market.
Regionally, North America was found to be the largest regional market due to the increasing patient
awareness, technological advancement, supportive government policies in terms of incentives and
investments, sophisticated healthcare infrastructure are the key factors attributing for its largest share.
Roche today announced results from the pivotal phase III CLL14 study in previously untreated chronic
lymphocytic leukaemia (CLL) showing that Venclexta/Venclyxto (venetoclax) plus Gazyva/Gazyvaro
(obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS).
Novartis announced that the US Food and Drug Administration (FDA) expanded the indication for
Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or
older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-
CP).
Leukemia Treatment Drugs Market Covers the Table of Contents With Segments, Key Players And
Region. Based on Product Type, Leukemia Treatment Drugs Market is sub segmented into Gleevec,
Sapacitabine, GA101, Vasaroxine, Tosedosat. On the Basis of Application, Market is sub segmented into
Hospitals, Research Institutes, Diagnostic Centers.
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on
“Global Leukemia Treatment Drugs Market Report 2019”
https://www.businessindustryreports.com/buy-now/160347/single .
MajorPlayers profiled in the Leukemia Treatment Drugs Market report incorporate: GSK, Pfizer, Novartis
AG, Roche, Celgene, Biogen, Genzyme Corporation, Eisai, Bristol Myers Squibb Company (BMS)
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Leukemia Treatment Drugs in these regions, from 2014 to 2023 (forecast),
covering: North America, Europe, Asia Pacific, Middle East & Africa and South America.
The report is a compilation of first-hand information, qualitative and quantitative assessment by
industry analysts, inputs from industry experts and industry participants across the value chain. The
report provides in-depth analysis of parent market trends, macro-economic indicators and governing
factors along with market attractiveness as per segments. The report also maps the qualitative impact of
various market factors on market segments and geographies.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation
(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost
Analysis, and Conclusion.
Report contents include